Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease
Although the primary endpoint of clinical response was not met at Week 16, ustekinumab IV reinduction showed numerical improvements in objective endpoints including inflammatory biomarkers and endoscopic outcomes compared with SC maintenance therapy. Safety and immunogenicity results were consistent with the established profile of ustekinumab.
Authors
- P. A. Makarchuk (ORCID: https://orcid.org/0000-0001-8053-8764)
- Annette Krummenerl
- Stéphane Nancey (ORCID: https://orcid.org/0000-0003-2088-1442)
- О. Б. Щукина (ORCID: https://orcid.org/0000-0001-8402-0743)
- Omoniyi J. Adedokun (ORCID: https://orcid.org/0000-0002-7678-3801)
- Wolfgang Mohl (ORCID: https://orcid.org/0000-0002-3284-211X)
- George DuVall
- Christopher Gasink
- Bruce Salzberg
- Udayakumar Navaneethan
- Helga‐Paula Török (ORCID: https://orcid.org/0000-0002-6883-5034)
- Stephan Borghorst
- Desirée Leemreis
- Milan Lukáš (ORCID: https://orcid.org/0000-0002-1463-3840)
- Christopher Busse
- Byong Duk Ye (ORCID: https://orcid.org/0000-0001-6647-6325)
- Parambir S. Dulai (ORCID: https://orcid.org/0000-0002-9514-2321)
- Mikael Lördal
- Pierre Blanc (ORCID: https://orcid.org/0000-0003-3802-0923)
- Francis A. Farraye (ORCID: https://orcid.org/0000-0001-6371-2441)
- Carlos Gutiérrez (ORCID: https://orcid.org/0009-0000-4159-9820)
- Bincy Abraham (ORCID: https://orcid.org/0000-0003-0308-1224)
- Taeoh Kim (ORCID: https://orcid.org/0000-0001-7252-5525)
- Simone Saibeni (ORCID: https://orcid.org/0000-0001-5677-2534)
- Wolfgang Reindl (ORCID: https://orcid.org/0000-0002-6982-8506)
- Thomas Krause (ORCID: https://orcid.org/0000-0003-4912-1703)
- Britta Siegmund (ORCID: https://orcid.org/0000-0002-0055-958X)
- Ana Echarri (ORCID: https://orcid.org/0000-0001-6690-7543)
- Anita Afzali (ORCID: https://orcid.org/0000-0002-4397-9576)
- Torsten Kucharzik (ORCID: https://orcid.org/0000-0002-0183-4483)
- Douglas C. Wolf (ORCID: https://orcid.org/0000-0003-1868-9574)
- Tomáš Vaňásek (ORCID: https://orcid.org/0009-0002-4276-2321)
- Kamal Patel (ORCID: https://orcid.org/0000-0003-2611-4260)
- Laura Loy (ORCID: https://orcid.org/0000-0002-5536-6152)
- Ulf Helwig (ORCID: https://orcid.org/0000-0001-6205-7633)
- Laurent Peyrin‐Biroulet (ORCID: https://orcid.org/0000-0003-2536-6618)
- María Dolores Martin‐Arranz (ORCID: https://orcid.org/0000-0002-1872-0917)
- Andrea E. van der Meulen‐de Jong (ORCID: https://orcid.org/0000-0001-9353-5431)
- Stefanie Howaldt (ORCID: https://orcid.org/0000-0001-9830-9126)
- Olga Fedorishina (ORCID: https://orcid.org/0000-0002-0155-676X)
- Brian G. Feagan (ORCID: https://orcid.org/0000-0002-6914-3822)
- Charles Randall (ORCID: https://orcid.org/0000-0001-7925-2208)
- Hyo Jong Kim (ORCID: https://orcid.org/0000-0002-9675-4557)
- Ignacio Marín‐Jiménez (ORCID: https://orcid.org/0000-0001-5424-2484)
- Xavier Calvet (ORCID: https://orcid.org/0000-0002-6278-9663)
- Heba Iskandar
- Yoram Bouhnik
- Alessandro Armuzzi (ORCID: https://orcid.org/0000-0003-1572-0118)
- Pilar López Serrano (ORCID: https://orcid.org/0000-0003-4488-5376)
- Caprioli Flavio
- Jessica Ravikoff Allegretti (ORCID: https://orcid.org/0000-0003-3585-2425)
- Sarah Camille Glover (ORCID: https://orcid.org/0000-0002-9899-0473)
- Manreet Kaur (ORCID: https://orcid.org/0000-0001-8716-8882)
- Tony Ma (ORCID: https://orcid.org/0000-0003-3629-8278)
- Ignacio Marín Jiménez
- Pierre Desreumaux (ORCID: https://orcid.org/0000-0002-6127-5281)
- Alexandra Kent (ORCID: https://orcid.org/0000-0003-0577-6177)
- William Holderman
- Scott D. Lee (ORCID: https://orcid.org/0000-0001-8936-8052)
- Herbert Deppe
- Renate Schmelz (ORCID: https://orcid.org/0000-0002-9012-2153)
- Elisabeth Schnoy (ORCID: https://orcid.org/0009-0005-7987-9517)
- R-M Lidon
- C. Janneke van der Woude (ORCID: https://orcid.org/0000-0003-3875-6957)
- Robert Hirten (ORCID: https://orcid.org/0000-0002-7980-9368)
- Jimmy K. Limdi (ORCID: https://orcid.org/0000-0002-1039-6251)
- Peter Hasselblatt (ORCID: https://orcid.org/0000-0002-1107-6516)
- Montserrat Rivero (ORCID: https://orcid.org/0000-0002-5834-1559)
- Douglas C. Wolf (ORCID: https://orcid.org/0000-0003-0330-8919)
- Thomas E. Baker (ORCID: https://orcid.org/0000-0002-3142-0767)
- Maciej Nazar
- Rodolfo Rocca
- Dawn Beaulieu
- Jeroen M. Jansen
- Irina Blumenstein (ORCID: https://orcid.org/0000-0002-7841-0494)
- Ji-Hye Park
- Bridget Godwin
- Jochen Klaus
- Stefan Schreiber (ORCID: https://orcid.org/0000-0002-6807-9822)
- Guillaume Boughen
Institutions
- Western University (CA)
- Johnson & Johnson (United States) (US)
- University of Washington (US)
- Erasmus MC (NL)
- University Hospital Augsburg (DE)
- Hospital General Universitario Gregorio Marañón (ES)
- Christian-Albrechts-Universität zu Kiel (DE)
- University Hospital Schleswig-Holstein (DE)
- Johnson & Johnson (Germany) (DE)
- Johnson & Johnson (Israel) (IL)
- Atlanta Gastroenterology Associates (US)
- University of Lübeck (DE)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-08-07
- DOI
- https://doi.org/10.1093/ibd/izaf163
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Celltrion Healthcare
- Mylan
- Boston Pharmaceuticals
- Celltrion
- Otsuka Pharmaceutical
- Tillotts Pharma
- Akebia Therapeutics
- Dr. Falk Pharma
- Genentech
- Samsung
- Allergan
- UCB Pharma